Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
about
Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive ReviewImaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative ApproachIrinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.High-grade KIT-negative sarcoma of the small bowel in a patient with chronic myeloid leukemia receiving long-term tyrosine kinase inhibitors.The role of chemotherapy and/or octreotide in patients with metastatic gastroenteropancreatic and hepatobiliary neuroendocrine carcinomaEstablishment and characterization of a new cell line, A99, from a primary small cell carcinoma of the pancreasSmall cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumorsMulticenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum.First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma.Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancyMetastatic Brain Neuroendocrine Tumor Originating from the Liver.Well-differentiated endocrine carcinoma originating from the bile duct in association with a congenital choledochal cyst.Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advancesNeuroendocrine carcinoma of the extrahepatic bile duct: A case reportRetinoblastoma-binding protein 2 (RBP2) is frequently expressed in neuroendocrine tumors and promotes the neoplastic phenotype.Pancreatic neuroendocrine tumors: biology, diagnosis,and treatmentA mixed adenoneuroendocrine carcinoma of the pancreas: a case report.Pancreatic involvement in small cell lung cancer.Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases.Pancreatic neuroendocrine tumors: a comprehensive review.Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma.Neuroendocrine Carcinoma of Gall Bladder: A Series of 19 Cases with Review of Literature.Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas.The safety of available treatments options for neuroendocrine tumors.Hypopharyngeal large cell neuroendocrine carcinoma.Undifferentiated carcinoma of the liver: a case report with immunohistochemical analysis.Mixed adenoneuroendocrine carcinoma derived from the cystic duct: A case report.Systemic therapy in incurable gastroenteropancreatic neuroendocrine tumours: a clinical practice guideline.Dramatic Response of a Metastatic Primary Small-Cell Carcinoma of the Pancreas to a Trial of Immunotherapy with Nivolumab: A Case Report.Combination therapies for primary hepatic neuroendocrine carcinoma: a case report.Two cases of neuroendocrine carcinoma of the gallbladder.The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs.Chemotherapy in NETs: When and how.Gastroenteropancreatic neuroendocrine tumors: incidence and treatment outcome in a single institution in Korea.Endocrine cell carcinomas of the colon and rectum: a clinicopathological evaluation.Neuroendocrine tumor of the common bile duct: a case report and review of the literature.Establishment of preclinical chemotherapy models for gastroenteropancreatic neuroendocrine carcinoma.Surgical treatment of pancreatic endocrine tumours in Italy: results of a prospective multicentre study of 262 cases
P2860
Q26768483-CDFA8436-8A18-4F52-A8D4-F3A913762C4EQ30491728-7BAEC2C6-30CF-4DBE-ADAC-EF2B9F906943Q33648996-22B3E657-E1C0-497E-9789-57BCD02CEFC6Q34283282-06263067-203D-43AC-B389-EC51EB183FDFQ34484273-87DA693A-75E7-4DE3-BF05-AD1B621ED7D8Q35234215-F34A47A4-AC8B-4984-9EC9-CC4E08F96870Q35681234-367B4703-5980-4497-B784-7751BD1D5413Q35713556-3B11EE26-CC7B-4C62-AFBB-2C668540F47BQ35907055-5E953A23-770A-4C78-940E-9F1B662542A5Q36352317-F69FEFFB-5DDC-4B52-9443-32AB2726ACD0Q36413831-7ADAA885-63EE-4995-B109-795C9BC13DD1Q36505881-01DFDCC5-D89A-4A94-832B-C3588828C022Q37055391-7F20A04E-F24B-4372-83D7-0211750ECF03Q37125550-F14B620D-C1EF-48AA-948B-0B550B532F38Q37153853-44A3FF0B-B77B-4348-80C4-9464F7DA681CQ37224297-F7E5E01A-613D-4DF6-904C-B5E47E06ACCCQ37354131-0432B2AA-31EA-4723-B17F-84AC80A5B248Q37415898-7ECD52F9-97FB-4911-BEDC-5338041A8BA8Q37537872-DBC12959-CBAE-4451-9D62-DFE7D419A8A4Q37687055-F131E78A-1E4E-456C-8D1F-893ACB666950Q37995947-36EA77F3-CE2D-44BD-8684-9BDBF3FFF148Q38371367-7FD5784D-8EA5-495A-BE99-6ED76552DBAFQ38553657-C0ADB907-BC12-44C7-9049-77A17EF72DAEQ39382625-1480121C-9540-4001-BCBC-110DC4431C38Q39433254-5D4EB487-A13C-4321-AA9C-F5AC8A0207DCQ40160738-59CB0E74-732F-42FC-B95B-427CC2F28324Q41192752-CBE4AA4E-FBA4-4FAF-9290-A5686C5D9934Q41302764-A05C603C-C4C7-4483-9BF4-57620CF7D88BQ41559421-6C2887F3-7320-40BA-8463-090B1741EF2BQ41601512-CEACF7BD-84C0-434F-B885-D9F9F75054BCQ41668455-1C2096D5-2538-42B1-AAB3-093366412573Q42862848-7C01F6A5-4A65-4196-97DA-D751054334F2Q42909384-8E16E312-C01D-443B-A8F5-A4123913F596Q47692261-79D0353B-8330-48F4-AA8E-EF9777FFB016Q51419447-30F0C74E-8D47-4B75-B562-27199C676C30Q53233612-72185097-5109-437D-9D4D-824B093997C6Q55019236-FC80F166-E5F4-458D-8916-69778EACAE02Q55044222-58177664-8BF8-4099-AD11-7C7605D3EC71Q57820051-615ACC20-52A4-4DD8-9902-8DAA3C4937AE
P2860
Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Cisplatin and etoposide as fir ...... atobiliary tract and pancreas.
@en
Cisplatin and etoposide as fir ...... atobiliary tract and pancreas.
@nl
type
label
Cisplatin and etoposide as fir ...... atobiliary tract and pancreas.
@en
Cisplatin and etoposide as fir ...... atobiliary tract and pancreas.
@nl
prefLabel
Cisplatin and etoposide as fir ...... atobiliary tract and pancreas.
@en
Cisplatin and etoposide as fir ...... atobiliary tract and pancreas.
@nl
P2093
P356
P1476
Cisplatin and etoposide as fir ...... atobiliary tract and pancreas.
@en
P2093
Atsushi Hagihara
Chigusa Morizane
Hideki Ueno
Kohei Nakachi
Masafumi Ikeda
Nobuyoshi Hiraoka
Satoru Iwasa
Shuichi Mitsunaga
Shunsuke Kondo
Takuji Okusaka
P304
P356
10.1093/JJCO/HYP173
P577
2010-01-04T00:00:00Z